QurCan Therapeutics Lakukan Perjanjian Strategis Riset dan Kerja Sama Dengan Lilly Untuk Memajukan Terapi Asam Nukleat Bagi Penyakit Sistem Saraf Pusat dan Saraf Perifer

World 1 source 1 country 🔦 Under-reported 19m ago

QurCan Therapeutics has entered into a strategic research and collaboration agreement with Lilly to advance nucleic acid therapies targeting central nervous system and peripheral nerve diseases.

QurCan is a biotechnology company specializing in pioneering drug delivery technologies for therapeutic applications.

In-depth summary · AI, neutral

Read the full story at the source Antara News (Jakarta, Indonesia) · ID ↗ Get the news on TelegramTop stories & under-reported picks, straight to your feed — free. Join →

QurCan Therapeutics Lakukan Perjanjian Strategis Riset dan Kerja Sama Dengan Lilly Untuk Memajukan Terapi Asam Nukleat Bagi Penyakit Sistem Saraf Pusat dan Saraf Perifer

More in World

Peter Max, whose colorful, psychedelic pop art was a key part of the culture in the 1960s, has died at age 88

The ‘godfather of AI’ claims that this technology is reaching a tipping point similar to that of the pandemic

The Red Cross in Beijing warns of a "moral red line" regarding autonomous weapons

After Messi's latest triumph with Inter Miami, here's how the list of the most decorated players in history looks.